- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Utilizing PDTs in the Future for Negative Symptoms
Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.
EP: 1.Discussing Negative Symptoms of Schizophrenia
EP: 2.The Clinical Burden of Negative Symptoms
EP: 3.Exploring the Shortage of Psychiatrists
EP: 4.The Potential of Prescription Drug Therapeutics (PDTs) in Schizophrenia
EP: 5.The Role of PDTs in Clinical Practice
EP: 6.Examining the CONVOKE Clinical Trial
EP: 7.The Future of Pharmacotherapy Plus PDTs
EP: 8.Economic Burden Associated With Schizophrenia
EP: 9.Key Background Information on Prescription Digital Therapeutics
EP: 10.Insurance Coverage of Prescription Digital Therapeutics
EP: 11.Managed Care Considerations for Prescription Digital Therapeutics
EP: 12.The Role of Advanced Practice Providers in Mental Health
EP: 13.Managing Negative Symptoms Associated With Schizophrenia
EP: 14.Current PDTs in Mental Health Disorders
EP: 15.Utilizing PDTs in the Future for Negative Symptoms
Patients with negative symptoms of schizophrenia represent a significant unmet medical need, with approximately 60% of individuals with schizophrenia experiencing these debilitating symptoms. These patients often endure longer hospital stays because their symptoms can be mistaken for depression, leading to unnecessary health care costs and delayed appropriate treatment. Patients with negative symptoms struggle with expressive, motivational, and experiential aspects of daily living that significantly impact their overall quality of life.
The potential for digital therapeutics to address these symptoms offers hope for patients who have limited treatment options. Clinical trials like the CONVOKE study examining CT-155 demonstrate that patients can benefit from interactive psychosocial interventions delivered through smartphone applications. These digital interventions could help patients develop motivation, improve social engagement, and enhance their ability to participate in academic, vocational, and family activities.
For patients living with schizophrenia, particularly those experiencing negative symptoms, digital therapeutics represent an opportunity to regain aspects of life that the disease has impacted. The potential for prescription digital therapeutics (PDTs) to help patients strengthen family relationships, pursue educational goals, and engage in meaningful work could reduce the burden of disability while improving individual outcomes. Patients deserve access to these innovative treatments that address the complex psychological and social challenges associated with schizophrenia’s negative symptoms.
